Biomarker Profiling in Stage 5 Chronic Kidney Disease Identifies the Relationship between Angiopoietin-2 and Atrial Fibrillation. (December 2018)

• Record Type: Journal Article
• Authors: Bontekoe, Jack; Lee, Justin; Bansal, Vinod; Syed, Mushabbar; Hoppensteadt, Debra; Maia, Paula; Walborn, Amanda; Liles, Jeffrey; Brailovsky, Eugene; Fareed, Jawed
• Is Part Of: Clinical and applied thrombosis/hemostasis. Volume 24:Number 9(2018)Supplement
• Page Start: 269S
• Page End: 276S
• Publication Date: 2018-12
• Subjects: atrial fibrillation -- chronic kidney disease -- hemodialysis -- angiopoietin-2 -- inflammation -- biomarkers; Hemostasis -- Periodicals; Thrombosis -- Periodicals; 616.13
• DOI: 10.1177/1076029618808909
• Languages: English
• ISSNs: 1076-0296

Abstract

Atrial fibrillation (AF) is prevalent in nearly 27% of patients with stage 5 chronic kidney disease on hemodialysis (CKD5-HD), suggesting a strong association between these 2 pathologies. It is hypothesized that the relationship between these 2 diseases may be mediated by inflammation. Angiopoietin-2 (Ang-2), a pro-inflammatory biomarker of endothelial instability, inflammation, and vascular remodeling, is elevated in CKD5-HD and AF, yet has not been evaluated in patients with concomitant AF and CKD5-HD. The aim of this study is to analyze circulating levels of inflammatory and thrombotic biomarkers in patients with concomitant AF and CKD5-HD. Plasma levels of Ang-2 were measured via sandwich enzyme-linked immunosorbent assay method in CKD5-HD patients (n = 96), patients with AF (n = 38), and controls (n = 50). Angiopoietin-2 was markedly elevated in CKD5-HD with comorbid AF as compared to CKD5-HD alone, and AF alone, respectively (13.05 ± 1.56 vs 9.57 ± 0.71 ng/mL; P = .00169; vs 2.48 ± 0.57 ng/mL; P < .0001). The results of this study suggest an additive effect of Ang-2 with coexistence of AF and CKD5-HD, which may be useful in the detection of AF within this patient population.